Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting
NCT ID: NCT05880316
Last Updated: 2023-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2023-05-28
2023-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Part 1: a cross-sectional study, looking at the prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) among nurses in Hospital Canselor Tuanku Muhriz (HCTM).
Part 2: a randomized controlled trial of intermittent fasting with MAFLD subjects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intermittent Fasting in Nonalcoholic Fatty Liver Disease
NCT04355910
Intermittent Fasting for NAFLD in Adults
NCT04899102
Intermittent Fasting and Metabolic Dysfunction Associated Fatty Liver Disease
NCT06664684
Effect of Indianized Version of Mediterranean Diet vs. Low Fat Diet on Hepatic Steatosis in Overweight Children and Adolescent With MASLD
NCT06768216
Fatty Liver Disease Collaborative Research in China
NCT02391168
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Approximately 100 participants who have fatty liver from Part 1 study, will be enrolled and randomized into Part 2. The intervention group will undergo intermittent fasting (3 fasting day:4 non-fasting days) while the control group will continue the usual standard care, for 8 weeks.
Measurements pre- and post-intervention include Fibroscan measurement, blood LiverFASt, anthropometric data, and exercise habit (IPAQ).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intermittent Fasting Group
IF regime: 3 fasting day: 4 non-fasting day. On fasting day - allows to eat restricted calorie diet (up to 70% total daily calorie intake) for 8 hours.
Intermittent Fasting
3:4 regime
Non-Fasting Group
Usual care. Not allowed to fast
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intermittent Fasting
3:4 regime
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* previous bariatric surgery
* liver cirrhosis
* liver cancer
* steatogenic drugs
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universiti Kebangsaan Malaysia Medical Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Khairul Najmi
Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Khairul Najmi M Nawawi
Role: PRINCIPAL_INVESTIGATOR
Gastroenterology Unit, Department of Medicine, Faculty of Medicine, UKM
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Canselor Tuanku Muhriz
Cheras, Kuala Lumpur, Malaysia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UKM/PPI/111/8/JEP-2023-276
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.